SOD1 and amyotrophic lateral sclerosis: Currently, gene therapy for ALS primarily focuses on SOD1 mutations, C9orf72 hexanucleotide repeat expansions, ATXN2 trinucleotide expansions, FUS mutations and sporadic disorder without known genetic component.